secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001193125-23-277136
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD reports Q3 net loss $1.4M; evaluates strategic alternatives
--------------------------------------------------------------------------

- Net loss from continuing ops $1.4M ($0.13/share) vs $14.6M ($1.58) in Q3 2022.
- License and service revenue negative $0.1M; gross royalties $1.2M for quarter.
- Operating expenses fell 88.2% to $1.7M on transition to royalty-based model.
- Board evaluating strategic alternatives including M&A, sale, or other transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000119312523277136/0001193125-23-277136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000119312523277136/d309650d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-277136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer